The market for an opportunity in the application of Advance Cancer Detection Technologies is predicted to go high as it is estimated to reach USD XX billion at the end of 2022 and is likely to grow at a modest CAGR during 2018-2022. The goal of this report is to assess the leading cancer detection technologies from 2016 to 2022. The assessment covers technologies in the following areas: pathology instruments, pathology kits, and tests, and image analysis tools. The number of technologies assessed in this study includes 35 technologies, 30 companies, and 30 products. In addition, 20 leading companies are identified for each technology based on recent market uptake and growth.
Pathologists will be able to take advantage of new cancer detection equipment that provides early cancer detection, allows for a more accurate diagnosis of non-small cell lung cancer, and provides a precise diagnosis of colon disease in 2022. The equipment will even measure the effectiveness of chemotherapy drugs. Technologies such as the NeoBase and NetFlow, which work by examining tissues or circulating tumor cells (CTCs), will assist pathologists in diagnosing five to 10 times more lung cancers than they diagnose today.
Pathology equipment markets are set to rise 14% in 2022, driven by innovations in cancer detection.
Advances in pathology equipment and instrumentation will give pathologists more insights into early detection, disease classification, and treatment beginning in 2022. Pathology has long relied on rapid, accurate, and early cancer detection to keep patients as healthy and well as possible. With new technologies used for screening and detection come new questions about the viability of various modalities in the future. This report discusses expected advances in advanced diagnostic imaging, noninvasive diagnostics, bioimaging advancements, big data analytics, and more. It also provides insights into the next generation of “liquid biopsies” on the horizon that can detect cancer before it even starts growing.
The pathologist is an expert who examines the body and its parts for signs of disease. This task usually begins with the microscope, and additional testing may be needed to confirm a diagnosis. Looking to 2022, technology for detecting cancers is expected to advance greatly as scientists learn more about cancer-related proteins and genetic mutations. As new tests are developed, physicians are likely to order more cancer screenings for those at risk of developing various forms of the disease.
Pathology laboratories are increasingly turning to advanced technologies for better accuracy in the early detection and diagnosis of cancer. While the markets for the technologies have been immature, the lack of laboratory resources has limited its adoption. However, with improvement in the quality of such services, advances in precision medicine, and increased interest from investors, the opportunity exists for startups to exploit this market. Cancer clinics need to stay current with advances in pathologic testing and diagnostic tools used to detect tumors and other growths in body tissue and fluids. Click here for the latest equipment to consider.
In recent years, the advancement in cancer diagnosis equipment has seen steady growth. Thus, it would be a prudent decision if buyers take an overview of the major technologies that are likely to shape the pathology landscape in 2019 and beyond. Available report: Pathology Equipment- An Overview. Pathology equipment sales are set to grow at a CAGR of almost 7% over the forecast period, and the market share of major suppliers increased during the same time.
Pathology instruments are an essential part of the healthcare equipment industry, serving as diagnostic and treatment instruments for in vitro testing. Increasing cancer rates, and an aging population, along with increased coverage of health insurance that includes advanced diagnostics and treatments, are expected to drive the market over the forecast period. The scope of this report is limited to professional-level pathology instrumentation in oncology, and which was incurred in the course of an in vitro procedure, and not during therapeutic or surgical procedures. Lung cancer accounts for about 34% of all new cancer cases, and a lung cancer diagnosis can be devastating regardless of whether it is early-stage or advanced. However, the good news is that early detection has been proven to improve lung cancer survival rates. Pathologists should certainly consider the following three technologies when seeking out tools to help make lung cancer diagnoses in 2022 and beyond.
New cancer-detection technologies may be worth commercialization in the next decade. By 2022, new systems may include those that can detect a vast range of cancers, especially early-stage and hard-to-spot cancers; can spot common symptoms, and integrate diagnostic results with electronic medical records for personalized treatment. Pathology equipment is increasingly adopting advanced technologies to bolster efficiency and cut costs. By 2022, it is estimated that around $6,754 million will be spent on the following cancer detection equipment: biosensors, fluorescent antibody staining (FAST) kit, immunofluorescence staining (IFS) instrument, image-guided surgery (IGS), and molecular pathology.
Pathology labs are evolving to meet the evolving demand in healthcare. In the year 2022, pathologists will see an advancement in cancer screening and treatment, using advanced pathology equipment.Pathology systems, devices, and services will rapidly progress in cancer care in the next few years. Technologies will be influenced by payer reimbursement and reimbursement decisions from private payers and government sectors, as well as new technology and treatment advances in precision cancer care, an overall aging population, and a growing cancer burden that can only be addressed with the transformation of healthcare delivery.
Pathology and imaging equipment market, by end-users such as hospitals, physician offices, clinics & other facilities, and service providers including outsourcing laboratories & cytology laboratories and a few more are estimated to reach an opportunity of more than $15.18 billion by 2022. The global Pathology equipment market has been witnessing the growing demand for advanced, automated, and digital pathology labs. The advancement in technology such as molecular diagnostics is driving the growth of the pathology lab market. However, strict government regulations and standards are hindering the path of growth. The cancer detection equipment market is divided into several types of equipment’s namely – immunohistochemistry (IHC) instruments, fluorescent in situ hybridization (FISH) instruments, high-resolution imaging systems, and microarray systems. Some of the major players identified in this report are BD Medical, Leica Biosystems, Merck KGaA, Bio-Rad Laboratories, and Thermo Fisher Scientific Inc.
Pathology is the study of diseases by doing a biopsy on tissue and examining it under the microscope. The Pathology Lab plays an important role in diagnosing different types of cancer, gallstone, heart diseases, thyroid problems, and kidney ailments. Pathologists play a vital role in determining a disease through the use of their advanced technologies that allow the detection of microscopic amounts of cells or molecules. Pathology equipment is used in laboratories around the world to diagnose diseases. These devices are increasingly automated and feature a wider range of capabilities. Pathology equipment comprises vacuum apparatus, laboratory incubators, hand-held analyzers, analytical balances, and liquid storage tanks. In this report, we analyze the global markets for pathology equipment in 2017 and provide our forecasts for 2022. We also take a look at some of the trends that will impact this market during the next five years.
As per the current trend, the market is expected to grow at a CAGR of more than 10%. The segmentation in the Global Pathology Equipments Market is based on product, operation, system, and end-user. The global market for pathology equipment is dominated by Italy and Germany. The leading companies such as KARL STORZ GmbH & Co. Kg, Olympus Corporation, LHU Healthcare Group PLC, MEDLEY SRL among others are striving to cater to the needs of laboratories worldwide by investing in research and development (R&D) to develop novel pathologic equipment that aid in a better diagnosis of their medical conditions. The report presents a comprehensive overview of the current market trends, growth drivers and restraints, opportunities, market challenges, and upcoming technologies. It identifies key players and their impact on the market.